These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31103736)

  • 1. Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Korani M; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Nanomedicine; 2019 Aug; 20():102013. PubMed ID: 31103736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Docetaxel Loading Conditions in Liposomes: proposing potential products for metastatic breast carcinoma chemotherapy.
    Vakili-Ghartavol R; Rezayat SM; Faridi-Majidi R; Sadri K; Jaafari MR
    Sci Rep; 2020 Mar; 10(1):5569. PubMed ID: 32221371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable and sustained release liposomal formulations of celecoxib: In vitro and in vivo anti-tumor evaluation.
    Matbou Riahi M; Sahebkar A; Sadri K; Nikoofal-Sahlabadi S; Jaafari MR
    Int J Pharm; 2018 Apr; 540(1-2):89-97. PubMed ID: 29371019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and characterization of stable nanoliposomal formulations of curcumin with high loading efficacy: In vitro and in vivo anti-tumor study.
    Karimi M; Gheybi F; Zamani P; Mashreghi M; Golmohammadzadeh S; Darban SA; Badiee A; Jaafari MR
    Int J Pharm; 2020 Apr; 580():119211. PubMed ID: 32156530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of PEGylated nanoliposomes containing crocin in mice bearing C26 colon carcinoma.
    Rastgoo M; Hosseinzadeh H; Alavizadeh H; Abbasi A; Ayati Z; Jaafari MR
    Planta Med; 2013 Apr; 79(6):447-51. PubMed ID: 23539350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
    Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
    Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
    Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation of liposomes containing IFN-gamma and their potentials in cancer immunotherapy: In vitro and in vivo studies in a colon cancer mouse model.
    Kateh Shamshiri M; Jaafari MR; Badiee A
    Life Sci; 2021 Jan; 264():118605. PubMed ID: 33096119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
    Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
    J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids.
    Kieler-Ferguson HM; Chan D; Sockolosky J; Finney L; Maxey E; Vogt S; Szoka FC
    Eur J Pharm Sci; 2017 May; 103():85-93. PubMed ID: 28263913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
    Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
    Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal encapsulation improves the antitumor efficacy of combretastatin A4 in murine 4T1 triple-negative breast cancer model.
    Mirzavi F; Barati M; Vakili-Ghartavol R; Roshan MK; Mashreghi M; Soukhtanloo M; Jaafari MR
    Int J Pharm; 2022 Feb; 613():121396. PubMed ID: 34942328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Tumor Efficacy of Pyrvinium Pamoate Nanoliposomes in an Experimental Model of Melanoma.
    Hatamipour M; Jaafari MR; Zangui M; Shakour N; Sahebkar A
    Anticancer Agents Med Chem; 2021; 21(17):2379-2384. PubMed ID: 33596812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
    Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
    Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Anti-Tumor Activity of Niclosamide Nanoliposomes Against Colon Carcinoma.
    Hatamipour M; Jaafari MR; Momtazi-Borojeni AA; Ramezani M; Sahebkar A
    Curr Mol Pharmacol; 2020; 13(3):245-250. PubMed ID: 31433764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
    Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
    Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotinylated HPMA centered polymeric nanoparticles for Bortezomib delivery.
    Rani S; Sahoo RK; Nakhate KT; Ajazuddin ; Gupta U
    Int J Pharm; 2020 Apr; 579():119173. PubMed ID: 32097684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell cytotoxicity, immunostimulatory and antitumor effects of lipid content of liposomal delivery platforms in cancer immunotherapies. A comprehensive in-vivo and in-vitro study.
    Nikpoor AR; Jaafari MR; Zamani P; Teymouri M; Gouklani H; Saburi E; Darban SA; Badiee A; Bahramifar A; Fasihi-Ramandi M; Taheri RA
    Int J Pharm; 2019 Aug; 567():118492. PubMed ID: 31271815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.